Pierre Fabre Medicament

8 trials 6 recruiting Commercial sponsor

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

6 Recruiting

2 Completed trials

8 Countries active

5 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase I (FiH)

Phase III: 2 Phase II: 2 Phase I (Other): 1 Phase I (FiH): 3

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Epstein-Barr virus associated lymphoproliferative disorder 2 Non-small cell lung cancer metastatic 2

Top IMPs

TABELECLEUCEL 2 HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN 1 NICOTINE RESINATE 1 STX-241 1 VERT-002 1

All trials

8 total

A clinical trial to learn about the safety and effects of VERT-002, a new anticancer drug for the treatment of patients with advanced solid … Recruiting

2024-512760-64-00 Phase I (FiH) 6 countries VERT-002
A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu… Recruiting

2023-510203-21-00 Phase I (FiH) 4 countries STX-241
A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting

2023-506759-51-00 Phase I (FiH) 4 countries
A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o… Recruiting

2024-516331-27-00 Phase I (Other) 4 countries
An open-label Phase 2 trial to investigate efficacy and safety of intraamniotic administrations of ER004 to male subjects with X-linked hypo… Recruiting

2024-512632-30-00 Phase II 4 countries HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDIN…
Open-label Phase 2 of tabelecleucel in Subjects with Epstein Barr Virus associated Diseases (EBVision) Recruiting

2024-516623-14-00 Phase II 5 countries TABELECLEUCEL
A study for subjects after organ or cell transplantation after failure of prior treatment Ended

2024-516622-57-00 Phase III 5 countries TABELECLEUCEL
Effects of Nicotine 1.5mg lozenge on smoking urges in moderate smokers Ended

2023-506787-13-00 Phase III 1 country NICOTINE RESINATE

Showing 1–8 of 8 trials

← All sponsors A–Z